Intraocular drug delivery systems containing excipients with reduced toxicity and related methods

• US 20050244472A1
• Filed: 03/28/2005
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Hughes, Patrick M., Boix, Michele, Delahaye, Laurent
• Application Number:
  US11/092,122
• Publication Number:
  US 20050244472A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/724 Cyclodextrins
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include one or more components which are effective in improving a release profile of a drug from the system, improving the stability of the drug, and improving the ocular tolerability of the drug. The present systems include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and an excipient component with reduced toxicity to retinal cells. The excipient component may include a cyclodextrin component that may be complexed with the therapeutic agents to provide advantages over existing intraocular drug delivery systems. The cyclodextrin component of the present systems have a reduced toxicity relative to benzyl alcohol or polysorbate 80. The drug delivery systems include one or more drug delivery elements such as microparticles, bioerodible implants, non-bioerodible implants, and combinations thereof. Methods of using and producing the drug delivery systems are also described.

Claims

1. A therapeutic drug delivery system useful for placement into a posterior segment of an eye of an individual, comprising:

a therapeutic component;

a cyclodextrin component complexed with the therapeutic component to enhance a therapeutic efficacy of the therapeutic component in treating an ocular condition; and

a polymeric component associated with the therapeutic component and cyclodextrin component in the form of a drug delivery element structured to be placed in the posterior segment of an eye of an individual.

2. The system of claim 1, wherein the therapeutic component comprises at least one therapeutic agent selected from the group consisting of steroids and steroid precursors.

3. The system of claim 1, wherein the therapeutic component comprises at least one steroid selected from the group consisting of cortisone, dexamethasone, prednisolone, prednisolone acetate, triamcinolone, and triamcinolone acetonide.

4. The system of claim 1, wherein the cyclodextrin component comprises at least one cyclodextrin selected from the group consisting of alpha-cyclodextrins, alpha-cyclodextrin derivatives, beta-cyclodextrins, beta-cyclodextrin derivatives, gamma-cyclodextrins, and gamma-cyclodextrin derivatives.

5. The system of claim 1, wherein the cyclodextrin component consists of at least one cyclodextrin selected from the group consisting of sulfobutyl ether 4-beta-cyclodextrin, hydroxypropyl beta-cyclodextrin, and hydroxypropyl gamma-cyclodextrin.

6. The system of claim 1, wherein the cyclodextrin component comprises an amount of hydroxypropyl gamma-cyclodextrin that is released in an amount from about 0.1% (w/v) to about 10% (w/v).

7. The system of claim 1, wherein the cyclodextrin component comprises an amount of sulfobutyl ether 4-beta-cyclodextrin that is released in an amount from about 0.1% (w/v) to about 10% (w/v).

8. The system of claim 1, wherein the cyclodextrin component comprises an amount of hydroxypropyl beta-cyclodextrin that is released in an amount from about 0.1% (w/v) to about 5% (w/v).

9. The system of claim 1, wherein the cyclodextrin component is present in an amount that is less toxic to retinal pigment epithelial cells than an equal amount of polysorbate 80 or benzyl alcohol when the cyclodextrin component is released from the element in the eye.

10. The system of claim 1, wherein the polymeric component comprises a polymer selected from the group consisting of poly-lactic acid (PLA), poly (lactide-co-glycolide) (PLGA), poly-1-lactic acid (PLLA), polycaprolactone, poly (ortho ester), and combinations thereof.

11. The system of claim 1, wherein the therapeutic component comprises triamcinolone, the cyclodextrin component comprises a cyclodextrin selected from the group consisting of sulfobutyl ether 4-beta-cyclodextrin, hydroxypropyl beta-cyclodextrin, and hydroxypropyl gamma-cyclodextrin, and the polymeric component comprises a poly (lactide-co-glycolide) polymer.

12. The system of claim 1, wherein the polymeric component is a non-biodegradable polymer.

17. A method for treating a posterior segment ocular condition, comprising injecting or implanting the system of claim 1 into the vitreous of an eye of an individual.

24. A method of manufacturing the system of claim 1, comprising:

encapsulating the therapeutic component in the cyclodextrin component to form complexes, and

adding the complexes to the polymeric component prior to formation of the element.

13. A therapeutic drug delivery system useful for placement into a posterior segment of an eye of an individual, comprising:

at least one drug delivery element selected from the group consisting of (i) poly (lactide-co-glycolide) polymeric microspheres comprising a cyclodextrin encapsulated drug;

(ii) monolithic poly (lactide-co-glycolide) polymeric implants comprising a cyclodextrin encapsulated drug;

(iii) biodegradable polymeric implants comprising a cyclodextrin encapsulated drug; and

(iv) non-biodegradable polymeric implants comprising a cyclodextrin encapsulated drug, the cyclodextrin being effective in enhancing a therapeutic efficacy of the drug when the drug delivery element is placed in the posterior segment of the eye by augmenting a release profile of the drug from the drug delivery element relative to a second substantially identical drug delivery element that includes the same drug and no cyclodextrin.

14. The system of claim 13, wherein the drug is selected from the group consisting of steroids and steroid precursors, and the cyclodextrin is selected from the group consisting of sulfobutyl ether 4-beta-cyclodextrin, hydroxypropyl beta-cyclodextrin, and hydroxypropyl gamma-cyclodextrin.

18. A method for treating a posterior segment ocular condition, comprising injecting or implanting the system of claim 13 into the vitreous of an eye of an individual.

15. A therapeutic drug delivery system useful for placement into a posterior segment of an eye of an individual, comprising:

a polymeric component effective in forming an implant useful for placement into the posterior segment of an eye of an individual;

a therapeutic component present in an amount effective in providing a desired therapeutic effect to an individual when the implant is placed in the posterior segment of the eye; and

a cyclodextrin component in an amount from about 0.5% (w/w) to about 25.0% (w/w) of the implant and effective in solubilizing a therapeutic agent of the therapeutic component.

16. The system of claim 15, wherein the therapeutic component comprises a corticosteroid, and the cyclodextrin component is present in an amount from about 5% (w/w) to about 15% (w/w) of the implant.

19. A method for treating a posterior segment ocular condition, comprising injecting or implanting the system of claim 15 into the vitreous of an eye of an individual.

20. A therapeutic drug delivery system useful for placement into a posterior segment of an eye of an individual, comprising:

a therapeutic component;

an excipient component present in an amount that is less toxic to retinal pigment epithelial cells relative to an equal amount of an agent selected from the group consisting of polysorbate 80 and benzyl alcohol; and

a polymeric component associated with the therapeutic component and excipient component in the form of a drug delivery element structured to be placed in the posterior segment an eye of an individual.

21. The system of claim 20, wherein the drug delivery element is substantially free of polysorbate 80 and benzyl alcohol.

22. The system of claim 20, wherein the excipient component comprises at least one excipient agent selected from the group consisting of sulfobutyl ether4 beta cyclodextrin, hydroxypropyl beta-cyclodextrin, hydroxypropyl gamma-cyclodextrin, carboxymethylcellulose, hydroxypropylmethyl cellulose, and boric acid.

23. The system of claim 20 provided in a composition useful for injection into the interior of an eye.